Profile data is unavailable for this security.
About the company
Immunovant, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing treatments for patients with autoimmune diseases. Its product pipeline includes batoclimab (IMVT-1401), and IMVT-1402, both of which are novel, fully human monoclonal antibodies that target the neonatal fragment crystallizable receptor (FcRn). Batoclimab is a subcutaneous injection with dosing. Batoclimab is observed to reduce immunoglobulin G (IgG) antibodies that cause inflammation and disease. Its product candidate, batoclimab, is dosed in small volumes and with a 27-gauge needle. It is developing batoclimab for myasthenia gravis (MG), thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP) and Graves’ disease (GD). IMVT-1402 is a fully human monoclonal antibody that inhibits FcRn. IMVT-1402 has also been observed in nonclinical studies to reduce IgG antibody levels. IMVT-1402 is delivered as a 2 mL simple subcutaneous injection.
- Revenue in USD (TTM)0.00
- Net income in USD-243.45m
- Incorporated2018
- Employees164.00
- LocationImmunovant Inc320 West 37Th StreetNEW YORK 10018United StatesUSA
- Phone+1 (917) 580-3099
- Fax+1 (302) 636-5454
- Websitehttps://immunovant.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Axsome Therapeutics Inc | 270.60m | -239.24m | 3.39bn | 545.00 | -- | 17.73 | -- | 12.52 | -5.20 | -5.20 | 5.96 | 4.03 | 0.5885 | 2.68 | 4.08 | 496,513.80 | -52.02 | -64.55 | -69.92 | -82.23 | 90.37 | -- | -88.41 | -227.05 | 3.52 | -35.93 | 0.4825 | -- | 440.80 | -- | -27.84 | -- | 77.86 | -- |
| Biohaven Ltd | 0.00 | -408.17m | 3.40bn | 239.00 | -- | 7.30 | -- | -- | -5.67 | -5.67 | 0.00 | 5.28 | 0.00 | -- | -- | 0.00 | -69.48 | -- | -79.29 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 28.43 | -- | -- | -- |
| Immunitybio Inc | 622.00k | -583.20m | 3.44bn | 628.00 | -- | -- | -- | 5,536.81 | -1.13 | -1.13 | 0.0012 | -0.875 | 0.0014 | -- | 0.246 | 990.45 | -134.71 | -112.76 | -377.77 | -316.07 | -- | -- | -93,866.88 | -37,700.74 | -- | -2.08 | 3.32 | -- | 159.17 | 67.62 | -40.00 | -- | 18.48 | -- |
| Simply Good Foods Co | 1.27bn | 140.76m | 3.46bn | 271.00 | 24.86 | 2.10 | 21.38 | 2.73 | 1.39 | 1.39 | 12.53 | 16.48 | 0.5977 | 6.91 | 8.56 | 4,671,908.00 | 6.65 | 3.66 | 6.95 | 3.83 | 37.26 | 38.90 | 11.12 | 6.80 | 3.09 | 9.26 | 0.1261 | 0.00 | 6.33 | 23.56 | 23.03 | 13.65 | 47.09 | -- |
| Ultragenyx Pharmaceutical Inc | 434.25m | -606.64m | 3.61bn | 1.28k | -- | 13.11 | -- | 8.31 | -8.33 | -8.33 | 5.91 | 3.35 | 0.286 | 1.49 | 7.63 | 340,320.50 | -39.96 | -33.35 | -48.63 | -38.30 | 89.59 | 93.13 | -139.70 | -154.71 | 2.49 | -- | 0.00 | -- | 19.52 | 53.18 | 14.25 | -- | 62.91 | -- |
| Alvotech SA | 93.38m | -551.73m | 3.64bn | 999.00 | -- | -- | -- | 39.00 | -2.40 | -2.40 | 0.4109 | -3.49 | 0.105 | 2.20 | 1.39 | 93,475.48 | -62.04 | -- | -81.72 | -- | -72.26 | -- | -590.83 | -- | 0.4614 | -1.29 | 7.52 | -- | 9.84 | -- | -7.43 | -- | -- | -- |
| Insmed Inc | 305.21m | -749.57m | 3.70bn | 912.00 | -- | -- | -- | 12.13 | -5.35 | -5.35 | 2.17 | -2.24 | 0.2044 | 0.8562 | 8.61 | 334,657.90 | -50.20 | -40.96 | -58.32 | -46.88 | 78.52 | 77.99 | -245.59 | -212.92 | 3.75 | -17.21 | 1.39 | -- | 24.39 | 98.78 | -55.66 | -- | -2.15 | -- |
| Immunovant Inc | 0.00 | -243.45m | 4.03bn | 164.00 | -- | 5.93 | -- | -- | -1.83 | -1.83 | 0.00 | 4.68 | 0.00 | -- | -- | 0.00 | -41.70 | -- | -44.49 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -34.60 | -- | -- | -- |
| Madrigal Pharmaceuticals Inc | 0.00 | -373.63m | 4.08bn | 376.00 | -- | 9.53 | -- | -- | -19.93 | -19.93 | 0.00 | 20.39 | 0.00 | -- | -- | 0.00 | -74.49 | -62.09 | -97.21 | -74.81 | -- | -- | -- | -- | -- | -- | 0.2217 | -- | -- | -- | -26.50 | -- | 132.01 | -- |
| Alkermes Plc | 1.66bn | 519.16m | 4.13bn | 2.10k | 8.09 | 3.39 | 6.96 | 2.49 | 3.02 | 2.07 | 9.79 | 7.20 | 0.8114 | 1.38 | 5.28 | 792,097.60 | 25.32 | 1.34 | 33.69 | 1.74 | 84.79 | 83.32 | 31.21 | 2.12 | 2.50 | -- | 0.1947 | 0.00 | 49.61 | 8.74 | 1,665.99 | -- | -7.10 | -- |
| Nuvalent Inc | 0.00 | -126.22m | 4.23bn | 92.00 | -- | 6.04 | -- | -- | -2.16 | -2.16 | 0.00 | 10.94 | 0.00 | -- | -- | 0.00 | -20.78 | -- | -21.70 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -54.20 | -- | -- | -- |
| Alpine Immune Sciences Inc | 58.88m | -32.18m | 4.24bn | 142.00 | -- | 11.89 | -- | 71.94 | -0.6827 | -0.6827 | 1.18 | 5.43 | 0.1767 | -- | 210.65 | 414,619.70 | -9.66 | -21.93 | -11.36 | -27.81 | -- | -- | -54.66 | -170.16 | -- | -- | 0.00 | -- | 95.84 | 142.30 | 44.28 | -- | -0.3253 | -- |
| Krystal Biotech Inc | 50.70m | 10.93m | 4.44bn | 229.00 | 1,759.30 | 5.65 | 263.14 | 87.56 | 0.0885 | 0.0885 | 1.84 | 27.58 | 0.0737 | -- | -- | 221,393.00 | 1.59 | -11.50 | 1.66 | -12.01 | 93.90 | -- | 21.56 | -492.85 | 17.55 | -- | 0.00 | -- | -- | -- | 107.81 | -- | 39.49 | -- |
| BridgeBio Pharma Inc | 9.30m | -643.20m | 4.47bn | 550.00 | -- | -- | -- | 480.44 | -3.95 | -3.95 | 0.0572 | -7.73 | 0.0159 | -- | -- | 16,914.54 | -111.72 | -72.44 | -148.01 | -89.72 | 73.71 | 94.41 | -7,021.94 | -1,225.66 | -- | -13.34 | 4.49 | -- | -88.02 | -- | -33.67 | -- | -40.94 | -- |
Data as of Apr 25 2024. Currency figures normalised to Immunovant Inc's reporting currency: US Dollar USD
21.70%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 7.88m | 5.42% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 5.68m | 3.91% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 4.02m | 2.77% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 3.22m | 2.21% |
| Point72 Asset Management LPas of 31 Dec 2023 | 2.68m | 1.84% |
| Perceptive Advisors LLCas of 31 Dec 2023 | 2.33m | 1.60% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Dec 2023 | 1.56m | 1.08% |
| Armistice Capital LLCas of 31 Dec 2023 | 1.44m | 0.99% |
| Alpine Global Management LLCas of 31 Dec 2023 | 1.40m | 0.96% |
| Adage Capital Management LPas of 31 Dec 2023 | 1.33m | 0.92% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
